Revolutionising cancer treatment, PreTT pioneers best-in-class Pretargeted radioligand therapies, surpassing traditional methods. Our exclusive pretargeting technology is set to transform radioimmunotherapies with monoclonal antibodies (mAbs), making a tangible impact in the fight against cancer.
| Website | https://www.pre-tt.com/ |
| Employees | 4 (4 on RocketReach) |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Cancer Treatment, Targeted Therapies, Cancer Treatment Innovation, Next Generation Therapies, Monoclonal Antibodies, Immunotherapy, Oncology, Radiopharmaceutical, Precision Medicine, Therapeutic Antibodies, Cancer Research, Nuclear Medicine, Molecular Imaging, Drug Development, Biotechnology, Pharmaceutical |
Looking for a particular PreTT employee's phone or email?
Francesco Sergi-Lindell is the CEO of PreTT.
4 people are employed at PreTT.